Nicox S.A.
ALCOX.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.04M
Close$
Share Statistics
| Market cap | $30.04 Million |
|---|---|
| Enterprise Value | $26.92 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.03 |
| Beta | 0.53 |
| Outstanding Shares | 88,130,706 |
Return
| Return on Equity | -561.14% |
|---|---|
| Return on Assets | -283.16% |
| Return on Invested Capital | -314.80% |
Valuation & Multiples
| P/E Ratio | -6.73 |
|---|---|
| PEG | 4.51 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.09 |
| Enterprise Value to EBIT | -1.35 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$3.00 M
Average shareholder expectationNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nicox S.A.
10 employees
CEO: Gavin Spencer Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric o...